Ponatinib

Ponatinib (sold under the brand name Iclusig) is an oral tyrosine kinase inhibitor (TKI) used to treat specific types of adult leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).It is mainly prescribed for patients whose cancer has the T315I mutation, which causes resistance to other TKIs, or who cannot tolerate or benefit from at least two prior TKI therapies. It is also used in combination with chemotherapy for newly diagnosed Ph+ ALL. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ponatinibum. Its PubChem CID is 24826799.

CAS No 943319-70-8
Molecular Formula C29H27F3N6O
Molecular Weight 532.60 g/mol
Synonyms 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

Frequently Asked Questions